Sigma-1 Receptor is a Pharmacological Target to Promote Neuroprotection in the SOD1

SOD1 G93A transgenic amyotrophic lateral sclerosis motoneuron neurodegenerative disease sigma-1 receptor

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2021
Historique:
received: 21 09 2021
accepted: 08 11 2021
entrez: 27 12 2021
pubmed: 28 12 2021
medline: 28 12 2021
Statut: epublish

Résumé

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized by the death of motoneurons (MNs) with a poor prognosis. There is no available cure, thus, novel therapeutic targets are urgently needed. Sigma-1 receptor (Sig-1R) has been reported as a target to treat experimental models of degenerative diseases and, importantly, mutations in the Sig-1R gene cause several types of motoneuron disease (MND). In this study we compared the potential therapeutic effect of three Sig-1R ligands, the agonists PRE-084 and SA4503 and the antagonist BD1063, in the SOD1

Identifiants

pubmed: 34955848
doi: 10.3389/fphar.2021.780588
pii: 780588
pmc: PMC8702863
doi:

Types de publication

Journal Article

Langues

eng

Pagination

780588

Informations de copyright

Copyright © 2021 Gaja-Capdevila, Hernández, Navarro and Herrando-Grabulosa.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Ther Adv Neurol Disord. 2009 Sep;2(5):319-26
pubmed: 21180622
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):577-597
pubmed: 29767748
Front Neurosci. 2019 Jun 27;13:532
pubmed: 31316328
Eur J Neurosci. 2003 Oct;18(8):2188-96
pubmed: 14622179
Neurosci Lett. 2019 Apr 1;697:34-48
pubmed: 29626651
Hum Mol Genet. 2017 Oct 1;26(R2):R91-R104
pubmed: 28977445
Ann Neurol. 1996 May;39(5):676-9
pubmed: 8619555
Neuroscience. 2012 Mar 29;206:60-8
pubmed: 22265729
Brain Res. 2011 Aug 11;1406:65-73
pubmed: 21733494
Neurotherapeutics. 2012 Oct;9(4):814-26
pubmed: 22935988
J Neuropathol Exp Neurol. 2011 May;70(5):349-59
pubmed: 21487309
Brain. 2015 Apr;138(Pt 4):875-90
pubmed: 25678561
Apoptosis. 2019 Feb;24(1-2):157-167
pubmed: 30387007
Adv Exp Med Biol. 2017;964:133-152
pubmed: 28315269
Neurosci Lett. 2014 Jan 24;559:174-8
pubmed: 24334165
Nat Rev Neurol. 2017 Aug;13(8):477-491
pubmed: 28731040
Hum Mol Genet. 2013 Jan 1;22(1):51-60
pubmed: 23026746
Genes Dev. 2009 Oct 1;23(19):2294-306
pubmed: 19762508
Br J Pharmacol. 2021 Mar;178(6):1336-1352
pubmed: 32761823
Nature. 1993 Mar 4;362(6415):59-62
pubmed: 8446170
Neuroscience. 2017 Sep 17;359:105-118
pubmed: 28723387
Neuroscience. 2009 Aug 4;162(1):31-8
pubmed: 19345724
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6591-5
pubmed: 8393571
CNS Neurol Disord Drug Targets. 2010 Dec;9(6):779-90
pubmed: 20942785
Lancet Neurol. 2019 Feb;18(2):165-176
pubmed: 30563778
Exp Neurol. 2004 Feb;185(2):232-40
pubmed: 14736504
EMBO Mol Med. 2016 Dec 1;8(12):1421-1437
pubmed: 27821430
Curr Neuropharmacol. 2018;16(1):97-116
pubmed: 28554311
Stroke. 2014 Nov;45(11):3304-10
pubmed: 25270629
Neurobiol Dis. 2014 Feb;62:218-32
pubmed: 24141020
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):3
pubmed: 33137196
Acta Myol. 2018 May 01;37(1):2-4
pubmed: 30079398
J Med Genet. 2020 Mar;57(3):178-186
pubmed: 31511340
Prog Neurobiol. 2008 May;85(1):94-134
pubmed: 18282652
Ann Neurol. 2011 Dec;70(6):913-9
pubmed: 21842496
Neurotherapeutics. 2018 Jan;15(1):178-189
pubmed: 28924870
Neuroscience. 2013 Jun 14;240:129-34
pubmed: 23458708
Neurochem Int. 2019 Oct;129:104492
pubmed: 31229554
Science. 2006 Jun 2;312(5778):1389-92
pubmed: 16741123
Cell Death Dis. 2019 Mar 1;10(3):210
pubmed: 30824685
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1604-9
pubmed: 11818550
Brain Res. 2007 Sep 5;1167:112-7
pubmed: 17689501
Cell. 2007 Nov 2;131(3):596-610
pubmed: 17981125
J Neurol Sci. 2006 Nov 1;249(1):13-8
pubmed: 16820172
Front Cell Neurosci. 2018 Jan 09;11:431
pubmed: 29375317
Lancet Neurol. 2017 Jul;16(7):505-512
pubmed: 28522181
Int J Mol Sci. 2021 Jun 28;22(13):
pubmed: 34203381
J Neurotrauma. 2011 May;28(5):831-40
pubmed: 21332255
Autophagy. 2011 Sep;7(9):985-92
pubmed: 21628996
Clin Neurophysiol. 2011 Aug;122(8):1660-70
pubmed: 21354365

Auteurs

Núria Gaja-Capdevila (N)

Institute of Neurosciences, Department Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Neus Hernández (N)

Institute of Neurosciences, Department Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Xavier Navarro (X)

Institute of Neurosciences, Department Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Mireia Herrando-Grabulosa (M)

Institute of Neurosciences, Department Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

Classifications MeSH